<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1386">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04851496</url>
  </required_header>
  <id_info>
    <org_study_id>NOV-0100-2</org_study_id>
    <nct_id>NCT04851496</nct_id>
  </id_info>
  <brief_title>Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - PAST Extension</brief_title>
  <acronym>AMYPRED-PAST</acronym>
  <official_title>A Study to Evaluate the Ability of Speech- and Language-based Digital Biomarkers to Detect and Characterise Prodromal and Preclinical Alzheimer's Disease in a Clinical Setting - PAST Extension Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novoic Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novoic Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate whether a set of algorithms analysing&#xD;
      acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment&#xD;
      in early stage Alzheimer's disease, based on archival spoken or written language samples, as&#xD;
      measured by the AUC of the receiver operating characteristic curve of the binary classifier&#xD;
      distinguishing between amyloid positive and amyloid negative arms. Secondary objectives&#xD;
      include (1) evaluating how many years before diagnosis of MCI such algorithms work, as&#xD;
      measured on binary classifier performance of the classifiers trained to classify MCI vs&#xD;
      cognitively normal (CN) arms using archival material from the following time bins before MCI&#xD;
      diagnosis: 0-5 years, 5-10 years, 10-15 years, 15-20 years, 20-25 years; (2) evaluating at&#xD;
      what age such algorithms can detect later amyloid positivity, as measured on binary&#xD;
      classifier performance of the classifiers trained to classify amyloid positive vs amyloid&#xD;
      negative arms using archival material from the following age bins: younger than 50, 50-55,&#xD;
      55-60, 65-70, 70-75 years old.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure is the area under the curve (AUC) of the receiver operating characteristic (ROC) curve of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) arms.</measure>
    <time_frame>Up to 85 years</time_frame>
    <description>Using archival spoken or written language samples as input.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The sensitivity, specificity and Cohen's kappa of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) arms using archival spoken or written language samples as input.</measure>
    <time_frame>Up to 85 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC, sensitivity, specificity and Cohen's kappa of the binary classifiers distinguishing between MCI and cognitively normal (CN) arms.</measure>
    <time_frame>Up to 85 years</time_frame>
    <description>Using archival spoken or written language samples as input in the following bins: 0-5 years, 5-10 years, 10-15 years, 15-20 years, 20-25 years before MCI diagnosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC, sensitivity, specificity and Cohen's kappa of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) arms.</measure>
    <time_frame>Up to 85 years</time_frame>
    <description>Using archival spoken or written language samples as input in the following bins: younger than 50, 50-55, 55-60, 65-70, 70-75 years old.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Preclinical Alzheimer's Disease</condition>
  <condition>Prodromal Alzheimer's Disease</condition>
  <condition>Alzheimer's Disease (Incl Subtypes)</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Arm 1: MCI amyloid positive</arm_group_label>
    <description>Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's or Mild Alzheimer's Dementia&#xD;
Positive amyloid PET or amyloid CSF status.&#xD;
MMSE 23-30 (inclusive)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: MCI amyloid negative</arm_group_label>
    <description>Non-AD Mild Cognitive Impairment (MCI)&#xD;
Negative amyloid PET or amyloid CSF status.&#xD;
MMSE 23-30 (inclusive)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: CN amyloid positive</arm_group_label>
    <description>Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline&#xD;
Positive amyloid PET or amyloid CSF status.&#xD;
MMSE 26-30 (inclusive)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: CN amyloid negative</arm_group_label>
    <description>Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline&#xD;
Negative amyloid PET or amyloid CSF status.&#xD;
MMSE 26-30 (inclusive)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be identified from participants of the AMYPRED study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects are fully eligible for and have completed the AMYPRED (Amyloid Prediction in&#xD;
             early stage Alzheimer's disease from acoustic and linguistic patterns of speech)&#xD;
             study.&#xD;
&#xD;
        (See https://clinicaltrials.gov/ct2/show/NCT04828122)&#xD;
&#xD;
          -  Subject has access to audio or written recordings created by them that are available&#xD;
             for collection.&#xD;
&#xD;
          -  Subject consents to take part in PAST extension study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject hasn't completed the full visit day in the AMYPRED study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emil Fristed, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novoic Limited</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Head of Clinical Operations</last_name>
    <phone>+447849522891</phone>
    <email>amypred@novoic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Re:Cognition Health</name>
      <address>
        <city>Birmingham</city>
        <zip>B16 8LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Centre Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Re:Cognition Health</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Centre Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Re:Cognition Health</name>
      <address>
        <city>London</city>
        <zip>W1G9JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Centre Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Re:Cognition Health</name>
      <address>
        <city>Plymouth</city>
        <zip>PL68BT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Centre Manager</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>April 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2021</study_first_posted>
  <last_update_submitted>April 6, 2022</last_update_submitted>
  <last_update_submitted_qc>April 6, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Preclinical Alzheimer's disease</keyword>
  <keyword>Prodromal Alzheimer's disease</keyword>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Normal Cognition</keyword>
  <keyword>Amyloid</keyword>
  <keyword>Speech</keyword>
  <keyword>Acoustic</keyword>
  <keyword>Language</keyword>
  <keyword>Linguistic</keyword>
  <keyword>Machine Learning</keyword>
  <keyword>Artificial Intelligence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

